Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma

Since 2021, the number of targeted drugs available for the treatment of relapsed or refractory lymphoma has been shrinking rather than growing. This falling number of treatment options comes with the announcement of withdrawals of several PI3K inhibitors in development for indolent B-cell lymphomas, including follicular lymphoma, because of an increased proportion of deaths in patients receiving PI3K inhibitors. Additionally, the histone deacetylase inhibitor, romidepsin, has been restricted to cutaneous T-cell lymphoma, because of the negative results of the Ro-CHOP study in patients with peripheral t-cell lymphoma.